Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market to reach the value of US$ 3,908.2 Mn by the end of 2030, reflecting a CAGR of 3.2% during the forecast period

The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is estimated to attract notable expansion opportunities in the upcoming years. This growth can be attributed to many factors including increasing occurrence of the antibiotic resistant strains development among population of all age groups.

Staphylococcus aureus refers to bacteria generally seen on the skin or nose of healthy individuals. Methicillin-resistant staphylococcus aureus (MRSA) can be defined as a staphylococcus aureus type, which shows resistance to beta-lactam antibiotic named methicillin.

Get the sample copy of report@ https://qyresearchmedical.com/sample/112019

Some of the prominent players in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include The Medicines Company, Basilea Pharmaceutica Ltd., Allergan, Merck & Co., Inc., Pfizer, Inc., and Theravance Biopharma. Presence of several prominent companies makes the competitive landscape of the market highly intense, which encourages enterprises to use organic as well as inorganic strategies in order to stay ahead in the competition.

Leading organizations in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market are investing heavily in the clinical trials and R&D projects, which are concentrated on the formulation of exclusive drug molecules. Moreover, many players are focusing on the launch of generic drugs against the presently available products that have lost the patent exclusivity.

The COVID-19 pandemic has shown impact major industries including the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. Companies have developed several policies and strategies in order to address this issue and ensure consistent revenue generation.

Several companies from the North America region, specifically the U.S., are increasing investments toward the R&D projects, which are focused on the development of screening tools for MRSA infection. This factor has helped in making North America as leading market region in the methicillin-resistant staphylococcus aureus (MRSA) drugs market. Moreover, Asia Pacific is expected to emerge as fastest growing region for the market in the years to come.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market: Snapshot

Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. The infection causes skin and tissue infection, and is transmitted by direct skin-to-skin contact. Global MRSA drugs market accounted for a revenue of US$ 2,967.0 Mn in 2016, and is estimated to reach the value of US$ 3,908.2 Mn by the end of 2025, reflecting a CAGR of 3.2% during the forecast period.

View full report@ https://qyresearchmedical.com/report/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-drug-class-lipopeptide-oxazolidinone-cephalosporin-tetracycline-lipoglycopeptide-folate-antagonist-route-of-administration-oral-and-parenter-017-2030/112019

According to CDC, two in every 100 people carry MRSA. Prolonged stay of patients in long-term health care facilities is a major factor giving rise to a serious issue of surplus MRSA infections. According to the Healthcare Cost & Utilization Project (HCUP), a family of health care databases in the U.S., the rate of deaths of hospitalized patients caused by MRSA infections is higher than non-hospitalized patients (4.7% vs. 2.1% respectively). Improved screening of antibiotic resistant strains of bacteria by using technologically advanced diagnostic tools, and upsurge in the consumption of antibiotics across the globe are the major factors expected to fuel the growth of global MRSA drugs market during the forecast period. Key companies are entering the distribution agreements with the emerging regional players to improve the accessibility of their anti-MRSA agents. Basilea Pharmaceutica, one of the leading MRSA drugs manufacturer, entered into a license agreement for its anti-MRSA antibiotic Zevtera (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (China). Such key strategies being adopted by the manufacturers is expected to propel the growth of MRSA drugs market during the forecast period. There is significant unmet need for the MRSA infection, which create huge opportunities for existing players and new entrants in the market. Also adopting the strategies such as establishing commercial partnerships for co-development and commercialization of anti-MRSA agents provide scope for opportunities in the global MRSA drugs market. However, lack of systematic surveillance for MRSA infection in developing countries is likely to hamper the growth of MRSA drugs market during 2017-2025.

The global MRSA drugs market is segmented on the basis of drug class, route of administration, and distribution channel. On the basis of drug class, the global MRSA drugs market is classified as lipopeptide, oxazolidinone, cephalosporin, tetracycline, lipoglycopeptide, folate antagonists, and others. Lipopeptide drug class held the maximum market share in 2016 in terms of revenue, owing to the established market for lipopeptides such as Daptomycin owing to efficient distribution by manufacturers and distributors across the globe. Tetracycline and Lipoglycopeptide are likely to register moderate CAGR by 2025. However, others drug class segment, which is comprised of fluoroquinolones, streptogramins, etc., is anticipated to witness significant CAGR during the forecast period, which is attributable to the rising prevalence of MRSA infection in community settings of the developing countries. Based on the route of administration, the global MRSA market is segmented into oral and parenteral. Parenteral segment accounted for highest revenue in 2016, and is expected to continue to lead the market during 2017-2025. The estimated dominance of the segment is attributed to its preference as a first line of therapy in the MRSA treatment. In terms of distribution channel, the global MRSA drugs market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Rising number of multispecialty hospitals worldwide, and improved supply of the generic MRSA drugs in the hospital pharmacies across the globe are the major factors for the dominance of hospital pharmacy segment in terms of revenue in 2016. However, online pharmacy is expected to grow at relatively significant CAGR during 2017-2025, due to availability of antibiotics on the online platform with attractive offers and discounts.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112019/2900

Geographically, global MRSA drugs market is divided into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for maximum revenue in 2016, owing to the strategic presence of key antibiotic manufacturing companies in the U.S. North America is estimated to remain dominant throughout the forecast period, which is attributable to the increasing investment by key players in the R&D of novel drug molecules against MRSA infection. However, rising awareness about the antibiotic resistant bacterial infections in the emerging economies of Asian countries, and rising incidence of hospital-acquired MRSA infection in India & China are the major factors for the estimated growth of Asia Pacific with relatively significant CAGR by 2025.

The prominent players operating in the global MRSA Drugs Market are Basilea Pharmaceutica Ltd., The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc. Investing in the R&D and clinical trials of unique drug molecules, and introducing the generic drugs against the existing products which have lost the patent exclusivity are the major strategies being adopted by key manufacturers to stay ahead in the rising competition.

The Global MRSA drugs Market has been segmented as given below:

Drug Class

  • Lipopeptide
  • Oxazolidinone
  • Tetracycline
  • Cephalosporin
  • Lipoglycopeptide
  • Folate Antagonist
  • Others

Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market

4. Market Overview
4.1. Drug Class Overview
4.2. Global MRSA Drugs Market Outlook

5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities

6. Epidemiological Assessment of Methicillin-resistant Staphylococcus Aureus (MRSA)

7. MRSA Drugs: Pipeline Analysis

8. MRSA Drugs Market: Competitive Landscape of Key Players

9. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Drug Class
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Drug Class, 2015–2025
9.3.1. Lipopeptide
9.3.2. Oxazolidinone
9.3.3. Cephalosporin
9.3.4. Tetracycline
9.3.5. Lipoglycopeptide
9.3.6. Folate Antagonist
9.3.7. Others
9.4. Market Attractiveness By Drug Class
9.5 Key Trends

10. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Route of Administration

……

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112019/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi